Dagenais S
Issues Emerg Health Technol. 2006 Nov(94):1-4.
(1) In viscosupplementation, a glycosaminoglycan (GAG) called hyaluronic acid (HA) is administered via intra-articular (IA) injection for patients with knee osteoarthritis (OA). (2) Evidence suggests modest short-term reductions in pain and improvements in function, and no superiority among HA products. (3) Adverse events are rare, benign, temporary, and likely associated with the IA injection. (4) Economic analyses of mixed quality suggest that HA may be cost effective compared with usual care. (5) Clinical practice guidelines and evidence suggest that this approach is most suitable for patients with mild to moderate knee OA, and in those for whom other approaches are contraindicated, or have failed.
（1）在粘弹性补充疗法中，一种名为透明质酸（HA）的糖胺聚糖（GAG）通过关节内（IA）注射用于膝骨关节炎（OA）患者。（2）有证据表明，短期内疼痛会适度减轻，功能会有所改善，且透明质酸产品之间并无优势差异。（3）不良事件很少见，为良性、暂时性的，且可能与关节内注射有关。（质量参差不齐的）经济分析表明，与常规治疗相比，透明质酸可能具有成本效益。（5）临床实践指南和证据表明，这种方法最适合轻度至中度膝骨关节炎患者，以及那些其他方法禁忌或无效的患者。
